Levodopa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Levodopa. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Dyskinesia | 16.5% |
| Nausea | 5.7% |
| Hallucinations | 3.9% |
| Confusion | 3.7% |
| Dizziness | 2.9% |
| Urinary tract infection | 2.3% |
| Depression | 2.2% |
| Headache | 2% |
| Vomiting | 1.9% |
| Dream abnormalities | 1.8% |
| Dystonia | 1.8% |
| Upper respiratory infection | 1.8% |
| Dyspnea | 1.6% |
| `on-off' phenomena | 1.6% |
| Back pain | 1.6% |
| Constipation | 1.5% |
| Dry mouth | 1.4% |
| Anorexia | 1.2% |
| Diarrhea | 1.2% |
| Insomnia | 1.2% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Source: FDA labeling via NIH DailyMed (set d2a64f14…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.